Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 5/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20827444 | 0.90 | GPR35 (0.62) | GPR35SMN1; SMN2MAPTHTTALDH1A1 | |
| SCHEMBL20827106 | 0.88 | GPR35 (0.56) | GPR35SMN1; SMN2MAPTLMNAALDH1A1 | |
| SCHEMBL1504061 | 0.86 | RAB9A (0.61) | GPR35RAB9ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL3647960 | 0.84 | GPR35 (0.57) | GPR35RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL7328333 | 0.82 | RAB9A (0.59) | RAB9ACYP1A2CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL3015758 | 0.82 | GPR35 (0.56) | GPR35SMN1; SMN2MAPTALDH1A1KDM4E | |
| SCHEMBL20827130 | 0.81 | GPR35 (0.60) | GPR35RAB9ACYP1A2CYP2C19MAPT | |
| Hydrochloric Acid SCHEMBL11811145 | 0.80 | RAB9A (0.51) | RAB9ACYP1A2CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL28799087 | 0.79 | ALDH1A1 (0.63) | GPR35LMNAALDH1A1PTPN1GAA | |
| SCHEMBL11486413 | 0.79 | HTT (0.61) | RAB9ACYP1A2CYP2D6CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981860-B2 | Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-04-20 | — | — | US | disclosed |
| US-20190135733-A1 | CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-05-09 | — | — | US | disclosed |
| EP-3456711-A1 | CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-03-20 | — | — | EP | disclosed |
| EP-0377112-B1 | Quinoxaline compounds and their preparation and use | NOVO NORDISK AS (DK) | 1994-08-24 | — | — | EP | disclosed |
| US-5075304-A | Nervous system disorders | NOVO NORDISK A/S (DK) | 1991-12-24 | — | — | US | disclosed |
| US-5061706-A | 2,3-QUINOXALINEDIONES FOR USE AS NEUROLEPTICS | NOVO NORDISK A/S (DK) | 1991-10-29 | — | — | US | disclosed |
| EP-0377112-A1 | Quinoxaline compounds and their preparation and use | NOVO NORDISK A/S (DK) | 1990-07-11 | — | — | EP | disclosed |
| EP-0344943-A1 | Imidazoquinoxaline compounds and their preparation and use | NOVO NORDISK A/S (DK) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981860-B2 | Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof | CASP1, CASP14, CASP2 | GPR35 2701/4885RAB9A 2065/4885CYP1A2 1447/4885 |
| US-20190135733-A1 | CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF | CASP1, CASP14, CASP2 | GPR35 2701/4885RAB9A 2065/4885CYP1A2 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.